Research programme: obesity therapy - Hybrigenics/Illumina

Drug Profile

Research programme: obesity therapy - Hybrigenics/Illumina

Alternative Names: Obesity therapy research programme - Hybrigenics/Illumina

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hybrigenics; Illumina
  • Developer Illumina
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Obesity

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Obesity in USA
  • 27 Jan 2007 Solexa Inc has been acquired and merged into Illumina
  • 11 Mar 2005 Lynx Therapeutics has merged with Solexa to form Solexa Inc
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top